Boehringer Ingelheim and Hypera Pharma side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Boehringer Ingelheim | Hypera Pharma |
|---|---|---|
| Phase 1 | Boehringer Ingelheim: 18 of its 45 programs at phase 1
and 13 more — sign in to see them all | 00% |
| Phase 2 | Boehringer Ingelheim: 15 of its 45 programs at phase 2
and 10 more — sign in to see them all | 00% |
| Phase 3 | Boehringer Ingelheim: 9 of its 45 programs at phase 3
and 4 more — sign in to see them all | Hypera Pharma: 1 of its 2 programs at phase 3
|
| Approved, new studies | Boehringer Ingelheim: 3 of its 45 programs at approved, new studies
| Hypera Pharma: 1 of its 2 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim21 readouts · 3 phase 3 | · | Boehringer Ingelheim, Dec ’26: 8 programs whose next study reaches primary completion, 1 in phase 3
and 3 more — sign in to see them all | · | Boehringer Ingelheim, Feb ’27: 2 programs whose next study reaches primary completion
| Boehringer Ingelheim, Mar ’27: 4 programs whose next study reaches primary completion
| Boehringer Ingelheim, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | Boehringer Ingelheim, Jun ’27: 1 program whose next study reaches primary completion
| Boehringer Ingelheim, Jul ’27: 2 programs whose next study reaches primary completion
| Boehringer Ingelheim, Aug ’27: 2 programs whose next study reaches primary completion
| · | Boehringer Ingelheim, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3
|
| Hypera Pharma2 readouts · 2 phase 3 | · | · | · | · | · | · | · | Hypera Pharma, Jun ’27: 2 programs whose next study reaches primary completion, 2 in phase 3
| · | · | · | · |
Changed in the last 90 days
Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Boehringer Ingelheim
New programs 3
- BI 4015092phase 1 · first study · Nov 3
- BI 3968621phase 1 · first study · Sep 25
- pumitamigphase 2 · first study · Sep 22 · Carcinoma, Non-Small-Cell Lung
Reached a new phase 1
- BI 3810477phase 2 · Nov 3 · Idiopathic Pulmonary Fibrosis
Study stopped 0
None
Primary completion later 7
- BI 3000202phase 1 · Dec 2026 → Dec 2029 (+36 mo) · moved Nov 13 · NCT06878365
- BI 3000202phase 1 · Oct 2026 → Feb 2027 (+5 mo) · moved Nov 12 · NCT07774325
- vsv-gp BI 1831169phase 1 · Dec 2027 → Jul 2028 (+7 mo) · moved Nov 10 · NCT05155332
- zongertinibphase 1 · Dec 2026 → Feb 2028 (+14 mo) · moved Oct 28 · NCT04886804
- survodutidephase 3 · Jun 2028 → Nov 2029 (+16 mo) · moved Oct 27 · NCT07855900
- BI 1815368phase 2 · Sep 2027 → Mar 2028 (+6 mo) · moved Oct 16 · NCT06962839
+1 more
- VSV-based Oncolytic Virus-expressing IL12/GSDME BI 3923948phase 1 · Feb 2028 → Jun 2031 (+39 mo) · moved Oct 13 · NCT07395258
Hypera Pharma
New programs 0
None
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Where they overlap
Conditions where at least two of them have programs: 1 in all. A program counts in each condition its studies name most.
| Condition | Boehringer Ingelheim | Hypera Pharma |
|---|---|---|
| Strokeboth · compare here | Boehringer Ingelheim in Stroke: 1 program
Their studies: Boehringer Ingelheim’s studies of Stroke in search | Hypera Pharma in Stroke: 1 program
Their studies: Hypera Pharma’s studies of Stroke in search |
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
No gene two of them both target, among the programs whose target is known.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
- Programs a company names but has not registered are counted apart (Boehringer Ingelheim: 21).